Untitled

Abstract

Leclercia adecarboxylata is a gram-negative bacillus. L. adecarboxylata has been isolated from various environments, such as food and water, and clinical specimens from patients with various diseases and ailments, such as pyelonephritis and sepsis. Although L. adecarboxylata infections are generally treated with β-lactam antibiotics, the emergence of multidrug-resistant strains reported in recent years has presented a major challenge in the clinical treatment of the infections. Thus, I searched for potential candidate compounds for developing new antibiotics that are effective against multidrug-resistant L. adecarboxylata. In a docking simulation performed to extract an inhibitor of the molecular chaperone GroEL, mizoribine was identified as a "hit."Notably, when L. adecarboxylata was cultured in a mizoribine-containing medium, its growth was inhibited at mizoribine concentrations of ≥0.63 mmol/L. considering these findings, I propose that mizoribine could serve as an effective new therapeutic agent for L. adecarboxylata infection. In the future, it will be necessary to investigate the effects of mizoribine on other bacterial species. INTRODUCTION:Leclercia adecarboxylata, a gram-negative, facultative anaerobic bacterium, was isolated from drinking water in 1962 and initially named Escherichia adecarboxylata, in the order Enterobacterales; however, the name was changed to L. adecarboxylata in 1986 1, 2, 3 . Since, then, L. adecarboxylata has been detected in diverse natural environments (such as natural surface waters, soils, and plant surfaces), animal sources, and foods 4 . Leclercia adecarboxylata infections in humans are rare, but humans can be infected under conditions of reduced immunity and overuse of non-steroidal anti-inflammatory drugs 1, 5 .